GTHX

G1 Therapeutics, Inc.

3.31 USD
-0.03 (-0.90%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

G1 Therapeutics, Inc. stock is down -12.2% since 30 days ago. The next earnings date is Jul 31, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 42.86% of the previous 7 May’s closed higher than April. In the last 10 Unusual Options Trades, there were 2 CALLs, 8 PUTs. 100% of analysts rate it a buy.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
22 May 16:21 19 Jul, 2024 10.00 CALL 401 10047
24 May 19:49 19 Jul, 2024 3.50 PUT 217 137
28 May 13:46 19 Jul, 2024 3.50 PUT 399 454
28 May 13:48 19 Jul, 2024 3.00 PUT 496 62
28 May 14:54 19 Jul, 2024 2.50 PUT 514 529
28 May 14:54 19 Jul, 2024 2.50 PUT 333 529
28 May 15:19 19 Jul, 2024 3.00 PUT 313 62
28 May 15:22 19 Jul, 2024 2.50 PUT 686 529
28 May 15:33 19 Jul, 2024 2.50 PUT 444 529
28 May 15:48 19 Jul, 2024 10.00 CALL 1000 10233

About G1 Therapeutics, Inc.

G1 Therapeutics, Inc. engages in the discovery, development, and commercialization of small molecule therapeutics. The company offers COSELA, which helps to decrease chemotherapy-induced myelosuppression in adult patients. It is also developing trilaciclib, a (CDK) 4/6 inhibitor that is in Phase III clinical trials for patients with first line colorectal cancer; and rintodestrant, an oral selective estrogen receptor degrader.

  • HC Wainwright & Co.
    Tue May 28, 12:31
    buy
    confirm
  • Needham
    Tue May 28, 11:01
    buy
    confirm
  • Needham
    Wed May 22, 12:13
    buy
    confirm
  • HC Wainwright & Co.
    Wed May 22, 08:37
    buy
    confirm
  • HC Wainwright & Co.
    Thu May 2, 13:36
    buy
    confirm
  • Needham
    Wed May 1, 11:59
    buy
    confirm